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Open access under the EA new series of organotelluranes were synthesized and investigated, and the structure–activity relation-
ships in cysteine proteases inhibition were determinated. It was possible to identify the relevance of
structural components linked to the reactivity of these compounds as inhibitors. For example,
dibromo-organotelluranes showed to be more reactive than dichloro-organotelluranes towards cysteine
cathepsins V and S. Besides, no remarkable enantio-selectivity was veriﬁed. In general the achiral organo-
telluranes were more reactive than the chiral congeners against cysteine cathepsins V and S. A reactivity
order for organochalcogenanes and cysteine cathepsins was proposed after the comparison of the inhib-
itory potencies of organotelluranes with the related organoselenanes.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.Se
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Figure 1. Ebselen, a selenium(II) compound, and AS-101, a inorganic tellurane.
Representative chalcogenated compounds that present pleiotropic biological
activities.1. Introduction
Recent studies about selenium and tellurium-containing bioac-
tive compounds have demonstrated the high potential of these
non-conventional compounds to the medicinal chemistry. These
compounds’ ability to act as enzyme mimetic has guided the syn-
thesis and evaluation of a large number of selenium and tellurium
compounds with different oxidation state. The glutathione peroxi-
dase (GPx)-like catalytic activity of selenium(II) compounds has
been largely evaluated. Besides the antioxidant and anti-inﬂamma-
tory properties1 of selenium compounds, in vitro and in vivo assays
have identiﬁed several biological activities of selenium compounds
including neuroprotective and convulsant effects,2 cancer preven-
tion,3 and apoptotic events.4 The most explored organoselenium(II)
compound is Ebselen which showed antioxidant and anti-inﬂam-
matory activity (Fig. 1).5 On the other hand, some tellurium(II)
compounds have also showed antioxidant properties including
mimetics of GPx.6 The most representative tellurium compound
is AS-101, an inorganic tellurane (hypervalent tellurium(IV) com-
pound) which has been investigated since 1990s by Sredni group
(Fig. 1). The pleiotropic activities such as anti-inﬂammatory,7
anti-microbial,8 anti-myeloma9,10 and melanoma treatment11, Par-R.L.O.R. Cunha), leandroh@
lsevier OA license.kinson’s disease,12 immunomodulator,13 besides treatment of ano-
genital warts,14 hair growth induction,15 stroke treatment where
reducing brain damage was associated to caspases inhibition,16
and tyrosine kinase17 and cysteine (papain, cathepsin B) proteases
inhibitors18 have been described for AS-101.
Organotelluranes have also been explored as inhibitors of cys-
teine proteases. The studies about organotelluranes as inhibitors
of cysteine proteases have demonstrated that these compounds
are more powerful cathepsin B inhibitors and for other cysteine
catepsins than AS-10119,20 and recently the potential of organotel-
luranes as anticonvulsant and inhibitors of caspases were re-
ported.21 It is noteworthy that, the published organotelluranes
were chosen randomically and few conclusions about the possible
structure–activity relationships could be identiﬁed. Thus, in this
work we describe our investigation in an attempt to determine
possible structure–activity relationships for a series of organotel-
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Figure 2. Organotelluranes with structural variations to be explored in the cysteine
cathepsins inhibition.
Cathepsin V
Cathepsin S
Figure 3. Inhibition proﬁle for cathepsins V and S using organotelluranes 1–6. Each
compound (1 lmol L1) was pre-incubated with active cathepsin for 2 min prior to
the addition of the substrate. The ﬂuorogenic substrate Cbz-Phe-Arg-AMC
(1 lmol L1) was used and the remaining enzyme activity was determined as a
percentage of the enzymatic activity without any inhibitor. The assays were
conducted in triplicate.
2010 L. Piovan et al. / Bioorg. Med. Chem. 19 (2011) 2009–2014luranes that was evaluated against two cysteine proteases, cathep-
sin V and S (Fig. 2).
The organotelluranes 1–6 were designed considering the possi-
bility of different activity between enantiomers or between chiral
and achiral congeners. It is known that the tellurium atom is the
electrophilic center of dihalogenated organotelluranes where one
Te-X (X = Cl, Br, I) bond is replaced by a Enz–S–Te bond after the
nucleophilic attack of the catalytic thiol residue from cysteine pro-
tease,18–20 hence we decided to explore the relevance of the halo-
gens (chlorine or bromine) as leaving groups bonded to the
tellurium atom.
The choice of the cysteine cathepsins was based on their biolog-
ical functions. Cathepsin V shares high protein sequence identity
with Cathepsin L (80%), but in contrast to the ubiquitously ex-
pressed Cathepsin L and broadly reported as an important tumor
treatment target, its expression is restricted to thymus, corneal
epithelium and testis.22 Cathepsin V has been involved in antigen
presentation in humans23 and also considered as a potential bio-
marker for colon tumors.24 Moreover, together with cathepsins L,
K and S, cathepsin V has been described to participate in athero-
sclerosis.25 On the other hand, cathepsin S has been associated in
several cancer stages, especially in angiogenesis and cell prolifera-
tion.26 It was also described the role of cathepsin S in cerebral
aneurysm indicating that this cysteine protease may promote the
progression of atherosclerosis by altering vascular remodeling in
atherosclerotic plaques.27
2. Results and discussion
2.1. Determination of the inhibitory activity of
organotelluranes against cathepsins S and V
The inhibition of cathepsins V and S were investigated by a ﬂuo-
rimetric enzyme assay using optimal reactional conditions for each
enzyme and the ﬂuorogenic dipeptide Cbz-Phe-Arg-AMC
(1 lmol L1) as previously described.28 The percentage of residual
enzymatic activity (%) was calculated by the ratio of the enzymatic
activity of cathepsin in the presence of 1 lmol L1 of the inhibitors
1–6 (A2) and the pattern enzymatic activity of cathepsin in the ab-
sence of inhibitor (A1) according to (Eq. 1). The residual activities of
cathepsin V and S after reaction with the compounds 1–6 are
shown in the Figure 3.
%Residualenzymaticactivity ¼ ðA2=A1Þ  100 ð1Þ
It was possible to observe that cathepsins V and S were strongly
inhibited by all organotelluranes at 1 lmol L1. For cathepsin V,
the most remarkable observation is that organotelluranes showedthe highest inhibitory activity (around 90%). However, by these
qualitative assays it was not possible to identify signiﬁcant differ-
ences between the enantiomers (2–3 or 5–6) or between the cong-
eners containing chlorine or bromine in their structure. In the
assays with cathepsin S, all organotelluranes reduced the enzy-
matic activity around 90%. It was possible to observe that the
dichloride telluranes inhibited around 85% of the activity of
cathepsin S while dibromide telluranes 4, 5 and 6 presented the
highest inhibitory activity (>90%), especially the compound 4 that
inhibited cathepsin S in 96%.
These assays were useful to identify the relevance of the chalco-
gen atom for the proﬁle of the compounds 1–6 as inhibitor of
cathepsins V and S. When these results are compared with that ob-
tained to organoselenanes cogeners it is evident that the chalcogen
atom is fundamental for the performance of the inhibitors since it
was observed that the percentage of inhibition of cathepsins V and
S by organotelluranes (1–6) are around 90 % while for organoselen-
anes the inhibitory activities were about 70–80 % at the same con-
ditions.29 Conclusions regarding the contributions of halogen and
details involving the stereochemistry of these compounds could
not be made by these tests. Thus, the second-order inactivation
rate constants (k2) of cathepsins V and S for compounds 1–6 were
determined, then all structural factors that inﬂuence each com-
pound activities against these enzymes were identiﬁed.
2.2. Second-order inactivation rate constants (k2)
determination for cathepsins V and S
Organotelluranes are very reactive irreversible inhibitors of cys-
teine proteases. Due to this high reactivity Cunha et al.20 reported
that by applying the Baici et al.30 model the more appropriated ki-
netic parameter to described the organotelluranes activities is the
second-order inactivation rate constants, k2, in which the inhibi-
tion reaction occurs by a one-step mechanism according to
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Scheme 1. Mechanism of irreversible inactivation (A) one step and (B) two steps.30
L. Piovan et al. / Bioorg. Med. Chem. 19 (2011) 2009–2014 2011Scheme 1A. Thus, it is inconvenient to determine Ki for these class
of inhibitor because the concentrations of these inhibitors are low-
er than Ki (k-2/k2) and the concentration of the reversible interme-
diate (EI) will be neglected.20,30 However, Ki is an adequate
parameter to less reactive inhibitors such as inorganic telluranes
where the inhibition is a two-step reaction (Scheme 1B).
The second-order inactivation rate constants (k2) of cathepsins
S and V by organotelluranes 1–6 were fundamental to identify
the structure–activity relationships for these compounds, they
were determined as previously described (Table 1).28 By the deter-
mination of k2 of cathepsins V and S by the organochalcogenanesTable 1
Second-order inactivation rate constants of the inhibition of cathepsins V and S by
organotelluranes 1–6
# k2 (mol L1 s1)
Cat. V Cat. S
OMe
Te
Cl Cl
1
11,600 ± 110 1300 ± 60
OMe
Te
Cl Cl
2
2400 ± 80 1800 ± 100
OMe
Te
Cl Cl
3
2500 ± 30 1800 ± 100
OMe
Te
Br Br
4
26,400 ± 800 4400 + 300
OMe
Te
Br Br
5
7400 ± 200 4900 ± 300
OMe
Te
Br Br
6
3900 + 300 2500 ± 3001–6 it was possible to conﬁrm that the telluranes are powerful
inhibitors of these enzymes. The importance of halogen could be
identiﬁed, and the dibromide compounds presented potency supe-
rior to the dichloride ones.
It is possible to verify from Table 1 that for each inhibitor the k2
for cathepsin V are higher than that of cathepsin S, demonstrating
that the organotelluranes 1–6 are more potent inhibitors for
cathepsin V than cathepsin S. It is important to highlight that 1
is almost ﬁve-fold more potent against cathepsin V than the chiral
congeners 2 and 3. In the case of 4, against cathepsin V this inhib-
itor is almost four-fold more potent than 5 and almost seven-fold
more potent than 6. In this way, it is clear that the achiral organo-
telluranes 1 and 4 are more potent inhibitors than their chiral
congeners. In the case of the inhibition of cathepsin S few differen-
tiations were observed between chiral and achiral congeners. Only
in the comparison of dibromo-organotelluranes was possible to see
that 5 is two-fold more potent than 6.
An inhibitory potency detailed analysis of these organotellur-
anes was more evident when we compare the second-order inacti-
vation rate constants (k2) with those obtained for the
organoselenanes congeners (Fig. 4).29
The ﬁrst observation, by this comparison, is the opposite selec-
tivity. While organotelluranes 1–6 inhibited cathepsin V faster
than cathepsin S, in the case of organoselenanes cathepsins S
was preferentially inhibited than cathepsin V. By consider the k2
of organotelluranes 1–6 and organoselenane 7–12, it is possible
to distribute the compounds 1–12 in three groups according to
the combinations of the chalcogen (Y = Se and Te) and halogens
(X = Cl and Br) and correlate them with the inhibition constants.
Thus, the ﬁrst group would be formed by the compounds contain-
ing tellurium and bromine in their structures (4–6, Table 1). It was
observed that these compounds are the most potent inhibitors
with all k2 greater than 3000 mol L1 s1. This group includes the
organotellurane 4, which undoubtedly was the strongest inhibitor
with a k2 = 26,400 L mol1 s1 against cathepsin V. At the other ex-
treme, in terms of potency of inhibitors, the compounds containing
selenium and chlorine in their structures (7–9, Fig. 4) showed the
lowest k2. In this case, it was observed that the inhibition constants
ranged between 500 and 1500 mol L1 s1, including the organose-
lenane 7 that showed the lowest k2 (500 L mol1 s 1) for inhibition
of cathepsin V. Intermediates k2 were observed to the compounds
that present in their structures tellurium bonded to chlorine (1–3,
Table 1), or selenium bonded to bromine (10–12, Fig. 4). In the case
of these compounds, the k2 ranged between 1300 and
4000 L mol1 s1, indicating a strong similarity in the potency of
compounds with different atomic composition. In this group, the
exception was the dichloro-organotellurane 1 with k2 = 11,600 L
mol1 s1 in the inhibition of cathepsin V.
Based on these observations, it is possible to correlate the
reactivity of compounds 1–12 toward the cysteine cathepsins,
with the structural characteristics of these inhibitors. Compounds
1–12 are hypervalent tetracoordinated selenium(IV) and tellu-
rium(IV) compounds with trigonal bipyramid geometry. The
hypervalent selenium and tellurium compounds that exhibit this
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Figure 4. Second-order inactivation rate constants of the inhibition of cathepsins V and S by organoselenanes 7–12.29
2012 L. Piovan et al. / Bioorg. Med. Chem. 19 (2011) 2009–2014type of geometry, exhibit some structural restriction: (i) the more
electronegative atoms occupy the axial position, while the less
electronegative atoms occupy the equatorial position in the mol-
ecule. The non-bonding electrons pair is located in the equatorial
position. (ii) Another detail is the charge distribution in mole-
cules, since each atom in the axial positions accommodates a
charge ½ while the central element accommodates a charge
of +1. The electronegativity of the atoms that compose the struc-
ture can be taken as a factor to predict stability and reactivity of
hypervalent compounds of selenium (IV) and tellurium (IV). Due
to geometry and charge distribution it is known for these com-
pounds that the lower the electronegativity of central atom and
the higher electronegative of the element at the axial position,
more stable will be the compound. Other important structural as-
pect is that compounds 1–12 are ortho-substituted and a non-
bonded YO (Y = Se, Te) intramolecular interaction occurs. Due
to this interaction, the strength of the bond Y–X (X = Cl, Br),31
could facilitate the leaving of X after a nucleophilic attack on
the chalcogen atom.
Given these considerations about the structure of hypervalent
compounds of selenium(IV) and tellurium(IV), one can use these
features to explain the reactivity of these compounds with the cys-
teine cathepsins V and S. In Scheme 2 it is shown the possible
mechanism of inhibition of cysteine proteases by organoselenanes
and organotelluranes. Under this proposal, the chalcogen (Y = Se,
Te) is the electrophilic center in the inhibitor 1–12 that undergoes
nucleophilic attack of thiol at the active site of the enzyme. In this
reaction a Y–X bound (X = Cl, Br) is broken and a new bound Y–S isY
E
E
E
A
A
A = axial
E = equatorial
A
YR1
:
R2
X
δ −1/2
δ −1/2
δ + 1
Y = Se, Te
X = Cl, Br
B
X
Scheme 2. (A) Spatial arrangement of tetracoordinated hypervalent selenium(IV) or t
molecule. (B) The charge distribution in the hypervalent selenium(IV) or tellurium(IV) co
and telluranes.formed (Scheme 1). Therefore, knowing that the nucleophile is
always the same (a thiol group from cathepsins S and V), it can
simplify the mechanism in terms of the electrophilicity of chalco-
gen and the ability to stabilize the negative charge generated on
the leaving group X.
Considering the electrophilicity of the chalcogen, it is known
that tellurium is less electronegative than selenium and, due to
its greater capacity to stabilize the negative charge, bromide is a
better leaving group than the chloride, we can explain the highest
reactivity of the dibromo-organotelluranes toward cysteine
cathepsins. Moreover, the Y–Br bond is longer and weaker than
the Y–Cl bond, favoring the bromide as a better leaving group than
chlorine. From these considerations, the results in Table 1 can be
interpreted as follows: (i) the inhibitors that contain in their struc-
tures Te-Br bounds are the most potent. In this case, the most elec-
trophilic center is combinated to better leaving group (k2 >2400
mol L1 s1); (ii) the inhibitors composed by Se–Cl are those with
the worst combination exhibiting smaller second-order inactiva-
tion rate constants (k2 = 500–1500 mol L1 s1). In this case, the
less electrophilic chalcogen and the worst leaving group were com-
bined; (iii) with intermediate potency are the inhibitor that con-
tain Se–Br bound, in this case the inhibitors have a good leaving
group but the lower electrophilicity of the chalcogen is unfavorable
to the reaction with the thiol moiety from cathepsins (k2 = 1300–
4000 mol L1 s1). In the case of Te–Cl containing inhibitors, the
electrophilic chalcogen favors the reaction with the cathepsins
but the leaving group is not so good. Because of these features,
the combination of chalcogen and halogen, one can then explain+N
NH
S:-
H
Ca
th
ep
sin
Y..
X
X
Bu
Ar
+N
NH
S
H
Ca
th
ep
sin
Y
Bu
X
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- X-
C
ellurium(IV) compounds showing the equatorial (E) and axial (A) position in the
mpounds. (C) Probable mechanism for inhibition of cysteine proteases by selenanes
L. Piovan et al. / Bioorg. Med. Chem. 19 (2011) 2009–2014 2013the similarities between the Se–Br and Te–Cl containing inhibitors,
and consequently the intermediate potency of these inhibitors.
Another important observation is the inﬂuence of chirality in
the potency of inhibitors 1–12. It was noted that the second-order
inactivation rate constants for cathepsins by these inhibitors, most
pairs of enantiomers showed similar potency to each other. Only in
the case of dibromides–organotelluranes one enantiomer (5) is
two-fold more potent than the other (6). Thus, one can conclude
that for the inhibitors 1–12 against cysteine cathepsins V and S
no signiﬁcant differentiation between pairs of enantiomers was
observed. However, comparing a pair of enantiomers with the
achiral congeners, the achiral compounds showed higher second-
order inactivation rate constant than the chiral congeners.3. Conclusions
By a rational design of a series of organotelluranes and by com-
parisonwith the organoselenanes congeners, it was possible to con-
clude that the structural aspects are directly linked to the reactivity
of these hypervalent compounds. The combination Te and Br lead to
very powerful cysteine proteases inhibitors while the worst combi-
nation was Se and Cl, that lead to less powerful inhibitors. Interme-
diates potencies were observed to the inhibitors that combined Se
and Br or Te and Cl in their structures. These results indicate that
the potency of this family of hypervalent compounds can be
modulated using the correct combination among Se, Te, Cl and Br.
4. Experimental section
4.1. Screening of inhibitory activity of cathepsins by
organotelluranes
The cathepsins kinetics of Cbz-Fr-MCA hydrolysis were per-
formed in the optimal conditions for each enzyme: Cathepsin B:
50 mmol L1 sodium phosphate buffer (pH 6.0) containing 200
mmol L1 NaCl and 1 mmol L1 EDTA; Cathepsin S: 50 mmol L1
sodium phosphate buffer (pH 6.5) containing 2.5 mmol L1 EDTA;
Cathepsin V and K: 50 mmol L1 sodium acetate buffer (pH 5.5)
containing 2.5 mmol L1 EDTA. The screening of the inhibition of
cathepsins was performed by the incubation of each cathepsin
with the organotelluranes 1–6 (1 lmol L1) for two min in the
appropriate buffer solution at 37 C, then the ﬂuorogenic substrate
Cbz-FR-MCA was added and the remaining enzyme activity was
determined. The remaining cathepsin activities were expressed
as a percentage of the activity of the control experiment.
4.2. Inactivation kinetics
Cathepsins activities were monitored spectroﬂuorometrically
using the ﬂuorogenic substrate Cbz-FR-MCA on a Hitachi F-2000
spectroﬂuorometer equipped with a thermostated cell holder.
The excitation and emission wavelengths were set at 380 and
460 nm, respectively. The continuous method was employed and
the inhibition of activated cysteine peptidases were carried out
in the presence of substrate and different concentrations of each
organotellurane, as described previously. The substrate concentra-
tions were kept 10-fold below the KM values. The kinetics of
cathepsin inactivation by organotellurane was obtained in pseu-
do-ﬁrst-order conditions. The inhibition reaction was monitored
continuously by the ﬂuorescence of the enzymatic-released AMC.
The hydrolysis progress curves were obtained in pseudo-ﬁrst-order
conditions and treated by non-linear regression according to Eq.
(1) as reported previously:
P ¼ ðvz=kobsÞ ½1 expðkobstÞ þ dwhere P is the product concentration (in our case it is proportional
to the ﬂuorescence of AMC) at a given time, vz is velocity of sub-
strate hydrolysis for zero time and kobs is the observed ﬁrst-order
rate of organotellurane-induced enzyme inactivation and d is the
basal ﬂuorescence before addition of the enzyme.
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